Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)
Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –
Royalty Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Royalty Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $238.64M, down 32.2% year over year. For fiscal 2025 it was $452.00M, up 22500.0% from the year before. The highest annual figure on record is $452.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $452.00M | +22500.0% |
| FY2024 | Dec 31, 2024 | $2.00M | -96.2% |
| FY2023 | Dec 31, 2023 | $52.00M | -70.6% |
| FY2022 | Dec 31, 2022 | $177.11M | -11.5% |
| FY2021 | Dec 31, 2021 | $200.08M | +661.1% |
| FY2020 | Dec 31, 2020 | $26.29M | -68.3% |
| FY2019 | Dec 31, 2019 | $83.04M | -78.9% |
| FY2018 | Dec 31, 2018 | $392.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $97.85M | -67.4% |
| Q1 FY2026 | Mar 31, 2026 | $39.79M | -21.2% |
| Q4 FY2025 | Dec 31, 2025 | $50.50M | +10000.0% |
| Q3 FY2025 | Sep 30, 2025 | $50.50M | +10000.0% |
| Q2 FY2025 | Jun 30, 2025 | $300.50M | +60000.0% |
| Q1 FY2025 | Mar 31, 2025 | $50.50M | +10000.0% |
| Q4 FY2024 | Dec 31, 2024 | $500.00K | 0.0% |
| Q3 FY2024 | Sep 30, 2024 | $500.00K | -99.0% |
| Q2 FY2024 | Jun 30, 2024 | $500.00K | 0.0% |
| Q1 FY2024 | Mar 31, 2024 | $500.00K | 0.0% |
| Q4 FY2023 | Dec 31, 2023 | $500.00K | -99.0% |
| Q3 FY2023 | Sep 30, 2023 | $50.50M | +98.0% |
| Q2 FY2023 | Jun 30, 2023 | $500.00K | -17.5% |
| Q1 FY2023 | Mar 31, 2023 | $500.00K | -99.5% |
| Q4 FY2022 | Dec 31, 2022 | $50.50M | -51.4% |
| Q3 FY2022 | Sep 30, 2022 | $25.50M | -71.8% |
| Q2 FY2022 | Jun 30, 2022 | $606.00K | -80.6% |
| Q1 FY2022 | Mar 31, 2022 | $100.50M | +3705.4% |
| Q4 FY2021 | Dec 31, 2021 | $103.82M | +1234.6% |
| Q3 FY2021 | Sep 30, 2021 | $90.50M | +1675.9% |
| Q2 FY2021 | Jun 30, 2021 | $3.12M | -45.9% |
| Q1 FY2021 | Mar 31, 2021 | $2.64M | -65.4% |
| Q4 FY2020 | Dec 31, 2020 | $7.78M | -51.0% |
| Q3 FY2020 | Sep 30, 2020 | $5.10M | -77.6% |
| Q2 FY2020 | Jun 30, 2020 | $5.78M | -73.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.64M | – |
| Q4 FY2019 | Dec 31, 2019 | $15.87M | – |
| Q3 FY2019 | Sep 30, 2019 | $22.72M | – |
| Q2 FY2019 | Jun 30, 2019 | $21.46M | – |
See a number that looks wrong?